MyMD Pharmaceuticals, Inc. – NASDAQ:MYMD
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 17 hours
MyMD Pharmaceuticals stock price monthly change
-11.77%
month
MyMD Pharmaceuticals stock price quarterly change
-17.43%
quarter
MyMD Pharmaceuticals stock price yearly change
+3.45%
year
MyMD Pharmaceuticals key metrics
Market Cap | 4.29M |
Enterprise value | 63.88M |
P/E | -4.69 |
EV/Sales | N/A |
EV/EBITDA | -4.32 |
Price/Sales | N/A |
Price/Book | 3.49 |
PEG ratio | 0.02 |
EPS | -6.4 |
Revenue | N/A |
EBITDA | -26.50M |
Income | -12.28M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeMyMD Pharmaceuticals stock price history
MyMD Pharmaceuticals stock forecast
MyMD Pharmaceuticals financial statements
| Jun 2023 | 0 | -4.16M | |
|---|---|---|---|
| Sep 2023 | 0 | 4.04M | |
| Dec 2023 | 0 | -2.36M | |
| Mar 2024 | 0 | -9.80M |
0%
Yield TTM
| Payout ratio | 0% |
|---|
| 2019 | |
|---|---|
| 2020 | |
| 2021 | |
| 2022 | |
| 2023 | 12.13% |
| Jun 2023 | 25249125 | 14.50M | 57.46% |
|---|---|---|---|
| Sep 2023 | 21825536 | 5.71M | 26.19% |
| Dec 2023 | 17862270 | 5.08M | 28.49% |
| Mar 2024 | 14493615 | 4.25M | 29.34% |
| Jun 2023 | -3.91M | 3.82M | 0 |
|---|---|---|---|
| Sep 2023 | -3.15M | 3.36M | 0 |
| Dec 2023 | -1.93M | 5.93M | -1.61M |
| Mar 2024 | -1.91M | 732.02K | -1.27M |
MyMD Pharmaceuticals alternative data
| Aug 2023 | 9 |
|---|---|
| Sep 2023 | 9 |
| Oct 2023 | 9 |
| Nov 2023 | 9 |
| Dec 2023 | 10 |
| Jan 2024 | 10 |
| Feb 2024 | 10 |
| Mar 2024 | 10 |
| Apr 2024 | 10 |
| May 2024 | 6 |
| Jun 2024 | 6 |
| Jul 2024 | 6 |
MyMD Pharmaceuticals other data
42.04%
-45.66%
of MYMD is owned by hedge funds
1.86M
-2.03M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Dec 2022 | 10000 | 0 |
| Aug 2023 | 175000 | 0 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Purchase | RIVARD PAUL officer: Chief Legal Officer | Common stock | 150,000 | $1.11 | $166,500 | ||
Purchase | RIVARD PAUL officer: Chief Legal Officer | Common stock | 25,000 | $1.12 | $28,075 | ||
Purchase | RIVARD PAUL officer: EVP of Operations, GC | Common stock | 10,000 | $1.53 | $15,300 | ||
Purchase | SILVERMAN JOSHUA director | Common Stock | 5,000 | $7.55 | $37,770 | ||
Purchase | SILVERMAN JOSHUA director | Common Stock | 10,000 | $6.7 | $66,960 | ||
Purchase | RIVARD PAUL officer: EVP of Operations, GC | Common stock | 15,000 | $6.03 | $90,450 | ||
Option | WHITE BILLY JOE | Common Stock | 109,500 | N/A | N/A | ||
Option | WHITE BILLY JOE | Restricted Stock Units | 109,500 | N/A | N/A | ||
Option | SILVERMAN JOSHUA | Common Stock | 109,500 | N/A | N/A | ||
Option | SILVERMAN JOSHUA | Restricted Stock Units | 109,500 | N/A | N/A |
| Patent |
|---|
Application Filling date: 29 Oct 2020 Issue date: 15 Apr 2021 |
Grant Utility: Method of treating coronavirus Filling date: 17 Feb 2020 Issue date: 16 Feb 2021 |
Grant Utility: Method of regulating tumor necrosis factor-alpha (TNF-.alpha.) for treating cancers, autoimmune disorders, and other disorders associated with chronic inflammation Filling date: 10 Feb 2020 Issue date: 17 Nov 2020 |
Application Methods of Regulating Oxidoreductase Activity for Treatment of Inflammation and Age-Related Disorders Filling date: 14 Jul 2020 Issue date: 29 Oct 2020 |
Grant Filling date: 4 Nov 2019 Issue date: 20 Oct 2020 |
Grant Utility: Method of treating viral infections Filling date: 14 Feb 2020 Issue date: 29 Sep 2020 |
Grant Filling date: 3 Dec 2019 Issue date: 28 Jul 2020 |
Application Filling date: 11 Nov 2019 Issue date: 9 Jul 2020 |
Application Filling date: 17 Feb 2020 Issue date: 11 Jun 2020 |
Application Filling date: 14 Feb 2020 Issue date: 11 Jun 2020 |
-
When is MyMD Pharmaceuticals's next earnings date?
Unfortunately, MyMD Pharmaceuticals's (MYMD) next earnings date is currently unknown.
-
Does MyMD Pharmaceuticals pay dividends?
No, MyMD Pharmaceuticals does not pay dividends.
-
How much money does MyMD Pharmaceuticals make?
MyMD Pharmaceuticals has a market capitalization of 4.29M.
-
What is MyMD Pharmaceuticals's stock symbol?
MyMD Pharmaceuticals, Inc. is traded on the NASDAQ under the ticker symbol "MYMD".
-
What is MyMD Pharmaceuticals's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of MyMD Pharmaceuticals?
Shares of MyMD Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
How many employees does MyMD Pharmaceuticals have?
As Jul 2024, MyMD Pharmaceuticals employs 6 workers, which is 40% less then previous quarter.
-
When MyMD Pharmaceuticals went public?
MyMD Pharmaceuticals, Inc. is publicly traded company for more then 11 years since IPO on 23 Jan 2014.
-
What is MyMD Pharmaceuticals's official website?
The official website for MyMD Pharmaceuticals is mymd.com.
-
Where are MyMD Pharmaceuticals's headquarters?
MyMD Pharmaceuticals is headquartered at 855 North Wolfe Street, Baltimore, MD.
-
How can i contact MyMD Pharmaceuticals?
MyMD Pharmaceuticals's mailing address is 855 North Wolfe Street, Baltimore, MD and company can be reached via phone at +856 8488698.
MyMD Pharmaceuticals company profile:
MyMD Pharmaceuticals, Inc.
mymd.comExchange:
NASDAQ
Full time employees:
6
Industry:
Biotechnology
Sector:
Healthcare
MyMD Pharmaceuticals, Inc., a clinical development stage pharmaceutical company, focuses on developing various therapeutic platforms to treat the causes of disease. The company is developing MYMD-1, a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines; and to delay aging and increase longevity, as well as treat autoimmune diseases and COVID-19-associated depression. It is also developing Supera-CBD, a synthetic derivative of cannabidiol for treating chronic pain, addiction, and epilepsy. The company was founded in 2014 and is headquartered in Baltimore, Maryland.
855 North Wolfe Street
Baltimore, MD 21205
Baltimore, MD 21205
CIK: 0001321834
ISIN: US62856X2018
CUSIP: 00973E409
